TERN logo

TERN
Terns Pharmaceuticals Inc

2,344
Mkt Cap
$6.11B
Volume
2.75M
52W High
$53.19
52W Low
$2.66
PE Ratio
-51.26
TERN Fundamentals
Price
$52.93
Prev Close
$52.93
Open
$52.96
50D MA
$48.94
Beta
0.99
Avg. Volume
6.79M
EPS (Annual)
-$1.03
P/B
5.91
Rev/Employee
$0.00
$2,745.87
Loading...
Loading...
News
all
press releases
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Pictet Asset Management Holding SA Boosts Stake in Terns Pharmaceuticals, Inc. $TERN
Pictet Asset Management Holding SA lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 42.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,577...
MarketBeat·3d ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from Oppenheimer
Oppenheimer restated a "market perform" rating and set a $58.00 target price on shares of Terns Pharmaceuticals in a research report on Monday...
MarketBeat·5d ago
News Placeholder
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
Merck heads into Q1 with strong Keytruda demand but rising pressure from generics, vaccines slump, and deal costs persist. Can it retain growth momentum?
Zacks·5d ago
News Placeholder
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in...
Business Wire·8d ago
News Placeholder
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?
Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.
Zacks·11d ago
News Placeholder
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 15, 2026 Insiders may stand to receive...
PR Newswire·17d ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. boosted their price target on Terns Pharmaceuticals from $44.00 to $44.50 and gave the stock an "overweight" rating in a research report on Tuesday...
MarketBeat·18d ago
News Placeholder
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to...
Business Wire·22d ago
News Placeholder
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Hold" from Brokerages
Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have earned a consensus rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat Ratings...
MarketBeat·22d ago
<
1
2
...
>

Latest TERN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.